title: Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
abstract: In order to study efficacy, toxicity and the long-term results of donor lymphocyte infusions (DLI), we retrospectively analyzed DLI given for relapse after conventional allogeneic hematopoietic stem cell transplantation (HSCT) in 30 patients with a median delay of 107.5 months after transplant and 58 months after DLI. After DLI, 15 patients established full donor chimerism, three patients developed grade III and one grade IV acute GVHD. A total of 15 patients achieved a disease response. Among the 14 patients with chronic myeloid leukemia (CML), 11 are alive at the last follow-up: five are in complete molecular response (CMR) and two in complete cytogenetic response (CCR) with no other intervention after DLI, three in CMR after imatinib mesylate given after DLI and one in complete hematological response after imatinib mesylate and reduced-intensity conditioning allogeneic SCT performed after DLI. At the time of the last follow-up, 19 (63%) patients died and 11 (37%) remain alive. The 3-year probability of survival for the entire population, CML patients and non-CML patients, was 60, 93, 62% after transplantation, and 48, 80 and 48% after DLI, respectively. A multivariate analysis demonstrated a significantly worse survival rate after transplantation for female recipients, advanced disease and acute leukemia before transplantation.
authors.affiliation: Service d'Hématologie Clinique, Hôpital Edouard Herriot, Lyon cedex, France. annesophie.michallet@voila.fr
authors.forename: A S
authors.initials: AS
authors.lastname: Michallet
authors.forename: F
authors.initials: F
authors.lastname: Nicolini
authors.forename: S
authors.initials: S
authors.lastname: Fürst
authors.forename: Q H
authors.initials: QH
authors.lastname: Le
authors.forename: V
authors.initials: V
authors.lastname: Dubois
authors.forename: S
authors.initials: S
authors.lastname: Hayette
authors.forename: J P
authors.initials: JP
authors.lastname: Bourgeot
authors.forename: J P
authors.initials: JP
authors.lastname: Tremisi
authors.forename: X
authors.initials: X
authors.lastname: Thomas
authors.forename: L
authors.initials: L
authors.lastname: Gebuhrer
authors.forename: M
authors.initials: M
authors.lastname: Michallet
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease; D019337:Hematologic Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome